Targeting cancer metastasis with antibody therapeutics.

Autor:	Yang H; Department of Chemical & Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland, USA., Kuo YH; Department of Chemical & Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland, USA., Smith ZI; Department of Chemical & Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland, USA., Spangler J; Department of Chemical & Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland, USA.; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Jazyk:	angličtina
Zdroj:	Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology [Wiley Interdiscip Rev Nanomed Nanobiotechnol] 2021 Jul; Vol. 13 (4), pp. e1698. Date of Electronic Publication: 2021 Jan 18.
DOI:	10.1002/wnan.1698
Abstrakt:	Cancer metastasis, the spread of disease from a primary to a distal site through the circulatory or lymphatic systems, accounts for over 90% of all cancer related deaths. Despite significant progress in the field of cancer therapy in recent years, mortality rates remain dramatically higher for patients with metastatic disease versus those with local or regional disease. Although there is clearly an urgent need to develop drugs that inhibit cancer spread, the overwhelming majority of anticancer therapies that have been developed to date are designed to inhibit tumor growth but fail to address the key stages of the metastatic process: invasion, intravasation, circulation, extravasation, and colonization. There is growing interest in engineering targeted therapeutics, such as antibody drugs, that inhibit various steps in the metastatic cascade. We present an overview of antibody therapeutic approaches, both in the pipeline and in the clinic, that disrupt the essential mechanisms that underlie cancer metastasis. These therapies include classes of antibodies that indirectly target metastasis, including anti-integrin, anticadherin, and immune checkpoint blocking antibodies, as well as monoclonal and bispecific antibodies that are specifically designed to interrupt disease dissemination. Although few antimetastatic antibodies have achieved clinical success to date, there are many promising candidates in various stages of development, and novel targets and approaches are constantly emerging. Collectively, these efforts will enrich our understanding of the molecular drivers of metastasis, and the new strategies that arise promise to have a profound impact on the future of cancer therapeutic development. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease. (© 2021 Wiley Periodicals LLC.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text